# **International Journal of Current Advanced Research**

ISSN: O: 2319-6475, ISSN: P: 2319-6505, Impact Factor: 6.614 Available Online at www.journalijcar.org Volume 8; Issue 02 (A); February 2019; Page No. 17192-17194 DOI: http://dx.doi.org/10.24327/ijcar.2019.17194-3212



## A PROSPECTIVE STUDY ON DEMYELINATING DISEASES OF CENTRAL NERVOUS SYSTEM IN A TERTIARY CARE HOSPITAL

### Sarala Divya A and Krishna Murthy A

Department of General Medicine, Andhra Medical College, Visakhapatnam

ARTICLE INFO	ABSTRACT
Article History: Received 15th November, 2018 Received in revised form 7th December, 2018 Accepted 13th January, 2018 Published online 28th February, 2019	<ul> <li>Introduction: Demyelinating diseases characterised by inflammation and selective destruction of CNS myelin and are most common cause of non traumatic disability in young</li> <li>Aim: To study clinical presentation, course, prevalence of primary and secondary demyelinating lesions and response to steroids and short term follow up</li> <li>Materials And Methods: Prospective study in teaching hospital from May 2016 to Content to the second s</li></ul>
Key words:	September 2017 of fifty suspected male and female of age > 13 years subjected to serological and radiological tests
Demyelinating diseases, primary, multiple sclerosis, secondary	<ul> <li>Results: Most common age group affected was 20-30 years, accounting for 30% of cases. 18% of cases were &lt;20 years of age, 22% and 14% were 31-40 and 41-50 years respectively. None of the patients were &gt; 60 years of age. 31 patients (62%) were females and 19 (38%) were males. 25 cases (50%) were transverse myelitis; 12 (24%) ADEM; 5 (10%) multiple sclerosis; 2 (4%) NMOSD and 6 cases (12%) were secondary demyelinating diseases. Paraparesis and paraplegia most common presentation (48%) followed by bladder involvement (32%). Quadriparesis and quadriplegia seen in 22%, Sensory involvement in 6%, INO 4%, motor and optic nerve involvement 4%, hemiparesis in 4% and ataxia was seen in one case.</li> <li>Conclusions: Demyelinating diseases of CNS are common in younger age group, females are most affected. Primary are more common than secondary .NMO responds poorly to steroids</li> </ul>

Copyright©2019 Sarala Divya A and Krishna Murthy A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

# INTRODUCTION

Demyelinating disorders of CNS are characterized by inflammation and selective destruction of central nervous system (CNS) myelin. The peripheral nervous system (PNS) is spared and most patients have no evidence of an associated systemic illness. Inflammatory demyelinating diseases of the central nervous system occur throughout the world and are the foremost cause. of the nontraumatic neurological disability in young adults Multiple sclerosis <sup>(1,2)</sup> is the most common of these disorders, others include acute transverse myelitis, Acute disseminated encephalomyelitis (ADEM) <sup>(3,4,5)</sup> and Neuromyelitis optica (Devics disease) <sup>(6,7)</sup>. Although these disorders are all similarly characterized by focal CNS demyelination they vary in their clinical course, prognosis, regional distribution, pathology and pathogenesis.

\*Corresponding author: Sarala Divya Department of general medicine, Andhra Medical College, Visakhapatnam

#### Aim

To study clinical presentation, course prevalence of primary and secondary demyelinating lesions and response to steroids and short term follow up.

### **MATERIALS AND METHODS**

This is prospective observational study conducted in Andhra medical college, over the period of 18 months from May 2016 to September 2017. This study was approved by the ethics committee of our College. The study population involves 50 cases of demyelinating disease of central nervous system. The patients were selected from general medical ward and neuro medical ward.

*Inclusion Criteria*: Any male or female patients more than 13 years of age with long tract involvement (like pyramidal tract, MLF, posterior column, cerebellar pathways) with or without optic nerve and bladder involvement.

*Exclusion Criteria*: Patients without evidence for long tract Involvement were excluded from this study

After taking due consent, detailed history, physical examination, appropriate blood investigations, CSF analysis

and imaging of patients done as deemed necessary. All the patients were treated with 1g IV methyl prednisolone for 5 days. Then put on oral prednisolone tapering dose and Azathioprine 2 mg/kg /d. All the patients were reassessed after 6 weeks.

## RESULTS

Age Distribution

Table	1	age	distribution	of	cases
-------	---	-----	--------------	----	-------

Age group in years	Number of cases (n=50)
<20 yrs	9
20-30	15
31-40	11
41-50	7
51-60	8
>60 yrs	0

#### **Gender Distribution**

Out of 50 cases, 31 were females and 19 were males.




Figure 1 Gender distribution among cases


#### **Clinical Presentation**

Paraparesis and paraplegia most common presentation (48%) followed by bladder involvement (32%). Quadriparesis and quadriplegia seen in 22%, sensory involvement in 6%, INO 4%, motor and optic nerve involvement 4%, hemiparesis in 4% and ataxia was seen in one case

Table 2 Clinical	presentation
------------------	--------------

Clinical presentation	Presentation in number	
Paraperesis and paraplegia	24	
Quadriparesis or quadriplegia	11	
Bladder involvement	16	
INO	2	
Sensory involvement	3	
Ataxia	1	
Hemiparesis	2	
Motor and optic nerve	2	
involvement	_	

Primary demyelinating diseases were more common than secondary in this study



**Figure 2** Frequency of primary & secondary demyelinating diseases 25 cases (50%) were transverse myelitis; 12 (24%) ADEM; 5 (10%) multiple sclerosis ; 2 (4%) NMOSD and 6 cases (12%) were secondary demyelinating diseases.




Figure 3 Frequency of demyelinating diseases

#### **Response to Pulse Steroid Therapy**

All the patients of this study were treated with pulse steroid regimen, INJ.METHYL PREDNISLONE 1G Daily for 5 days




Figure 4 Response of demyelinating diseases to steroids

### DISCUSSION

In this study, the age distribution showed that younger age groups were more affected , 70% of the patients belong to less than 40 years of age and no cases were seen in more than 60 years of age. This is in accordance with literature that demyelinating diseases are most common in young age. The median age of presentation is 23 years while the study by Sheffali Gulati *et al* <sup>(8)</sup> the median age at initial presentation was 7 years (range: 1-12 years). The mean age of presentation was 10.5 years in a Canadian study of Banwel.B *et al* <sup>(9)</sup>.

With regards to the sex predilection, females were more affected (62%), than males (38%). In prospective study of SHANIJA.P *et al* <sup>(10)</sup>, similar to our study females were more affected (58%), than males (42%). In prospective nation vide dutch study <sup>(11)</sup>, the ratio between females and males in all demyelinating diseases patients did not differ significantly between the presenting phenotypes.

The clinical presentation varied from motor weakness in the form of paraplegia, paraperesis, quadriplegia, quadriparesis, monoperesis, or rarely hemiplegia, sensorv involvement in the form of paraesthesia, brain stem involvement in form of bilateral INO, optic nerve involvement with optic atrophy, cerebellar ataxia, and bladder involvement. In our study, Paraparesis and paraplegia was most common presentation (48%) followed by bladder involvement (32%). Quadriparesis and quadriplegia seen in 22%, sensory involvement in 6%, INO 4%, motor and optic nerve involvement 4%, hemiparesis in 4% and ataxia was seen in one case. Review of literature showed similar presentation in most of the studies.

In our study, 50% of cases were transverse myelitis, 24% ADEM, 10% multiple sclerosis while in prospective Dutch study, multiple sclerosis was most common (33%), and transverse myelitis (9%); ADEM (29%) and NMOSD (5%) accounted for rest of cases. In prospective study of SHANIJA.P *et al*, transverse myelitis accounted for 42 %, multiple sclerosis 24%, ADEM 22%. In Canadian study of Banwell B *et al*, the most common presentations were optic neuritis (23%), ADEM(22%), and transverse myelitis(22%) In our study, secondary demyelination accounted for 12% of cases while in study of SHANIJA.P *et al*, secondary demyelination was seen in 8%.

In our study, multiple sclerosis responded well to steroids while NMO showed very minimal response . This is similar to study of SHANIJA.P *et al*, 75% of multiple sclerosis and 50% transverse myelitis showed good response while NMO showed no response. In the retrospective study of Sheffali Gulati *et al*, Steroids caused significant improvement in acute episodes of demyelination. However, recurrent demyelinating disorders like multiple sclerosis and NMO required long-term immunomodulation. Azathioprine currently is the most favored long-term immunomodulator used in NMO. Interferon- $\beta$  and glatiramer acetate are currently recommended for multiple sclerosis. However, azathioprine may be a suitable alternative in a resource-limited setting.

All the patients were followed up for six weeks after steroid therapy. The recovery form neurological impairment was good in 75% of MS patients , 50% of the idiopathic demyelinating transverse myelitis patients

## CONCLUSIONS

Demyelinating disorders of the central nervous system are common among younger age group Females are more affected than males. Primary demyelinating diseases are more common than secondary demyelinating diseases. Most of the patients presented with pyramidal tract involvement followed by bladder involvement. NMO responds poorly to steroids.

## Limitations of This Study

Small sample size . Long term follow up required

## References

- 1. Noseworthy J. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999;399:Suppl:A40-A47.
- 2. Miller,DH ,grossman RI reingold SC Mcfarland,HF ,The role of magnetic resonance techniques in understandinding and managing multiple sclerosis.
- 3. Rust RS (2000). Multiple sclerosis, acute disseminated encephalomyelitis, and related conditions. Seminars in Pediatric Neurology 7:66-90.
- 4. Poser CM & Brinar VV (2007). Disseminated encephalomyelitis and multiple sclerosis: two different diseases a critical review. Acta Neurologica Scandinavica 116:201-206.
- Leake JAD, Albani S, Kao AS, *et al.* Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004;23:756–764
- Wingerchuk DM Weinshenker BG neuromyelitis optica current treatment options neurology 2005;7; 173-182
- Wingerchuk DM & Lucchinetti CF. (2007). Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Current Opinion in Neurology 20:343-350.
- Sheffali Gulati *et al*, acquired demyelinating disorders of central nervous system; Ann Indian Acad Neurol. 2015 Sep; 18(Suppl 1): S48–S55. doi: 10.4103/0972-2327.164829
- 9. Incidence of acquired demyelination of the CNS in Canadian children, Banwell .B *et al* 2009 Jan 20;72(3):232-9. doi: 10.1212/01
- 10. SHANIJA.P *et al*, analysis of 50 cases of demyelinating diseases of central nervous system.
- 11. C.L.de Mol *et al*, Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study 2018; 265(6): 1310–1319.

### How to cite this article:

Sarala Divya A and Krishna Murthy A (2019) ' A Prospective Study On Demyelinating Diseases Of Central Nervous System In A Tertiary Care Hospital', *International Journal of Current Advanced Research*, 08(02), pp. 17192-17194. DOI: http://dx.doi.org/10.24327/ijcar.2019.17194.3212

\*\*\*\*\*\*